GHRP-2
ProtocolProtocol design for GHRP-2 starts with pharmacokinetics and ends with calendar planning. The compound's ~15-60 min half-life via subq administration places it in the multi-daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.
Key Takeaways
Scheduling lens: GHRP-2's ~15-60 min half-life via subq places it in the multi-daily-dosing bucket. Mechanism: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Protocol calendar planning for GHRP-2 is shaped by mechanism, pharmacokinetics, and operational reality. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.
Cycle length and off-cycle planning
Standard GHRP-2 cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Daily and weekly timing
GHRP-2 with a ~15-60 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 2-3x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any GHRP-2 protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most GHRP-2 schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
For weekly timing scheduling, GHRP-2 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for GHRP-2 in cycle design starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for GHRP-2 in pulse strategies is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For loading phase scheduling, GHRP-2 is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-300 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-300 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 100-300 mcg | 2-3x daily SubQ |
| Maintenance phase | SubQ | 70-300 mcg | Ongoing with periodic pauses |
Dose timing for GHRP-2 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
GHRP-2 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- GHRP-2 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with GHRP-2's mechanism in protocol / scheduling / cycling protocols.
- GHRP-2 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with GHRP-2's mechanism in protocol / scheduling / cycling protocols.
- GHRP-2 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with GHRP-2's mechanism in protocol / scheduling / cycling protocols.
- GHRP-2 + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with GHRP-2's mechanism in protocol / scheduling / cycling protocols.
More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy.
Lens-specific safety considerations for protocol / scheduling / cycling use of GHRP-2: More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| GHRP-2 | Growth hormone releasing peptide | ~15-60 min | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Daily timing for GHRP-2?
Cycle length and off-cycle period?
Best practice for re-cycling?
Stack timing relative to training and meals?
What does GHRP-2 stack well with?
What is the mechanism of action of GHRP-2?
Start a GHRP-2 Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified GHRP-2 and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 817 Da
- Sequence length
- 6 aa
- Half-life
- ~15-60 min
- WADA
- Banned (S2)
- FDA
- Approved in Japan for GH stimulation testing only
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-2 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for GHRP-2
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised